Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock

Sepsis Clinical Trial

— Cascade  

Official title:

Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00922870
• Other study ID #: 1450
• Status: Completed
• Phase: N/A
• First received: June 15, 2009
• Last updated: April 4, 2017
• Start date: April 2009
• Est. completion date: March 2013

Study information

• Verified date: April 2017
• Source: Baxter Healthcare Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Septic shock is a major cause of mortality and morbidity in critically ill patients. Septic Shock is associated with an overwhelming, systemic overflow of pro inflammatory and anti-inflammatory mediators, which leads to generalized endothelial damage, multiple organ failure, and altered cellular immunological responsiveness. Although our understanding of the complex pathophysiological alterations that occur in septic shock has increased greatly as a result of recent clinical and preclinical studies, mortality associated with the disorder remains unacceptably high, ranging from 30% to 50%. To date, attempts to improve survival with innovative, predominantly anti-inflammatory therapeutic strategies have been disappointing. A standard hemofiltration rate of 35 ml/kg/hour has been successfully used to treat acute renal failure. However, this dose does not alter plasma levels of inflammatory mediators, suggesting that its ability to clear these mediators is suboptimal. Higher doses of hemofiltration (up to 120 ml/kg per hour) have been demonstrated to improve cardiac function and hemodynamics in several animal models of sepsis. High-volume hemofiltration (HVHF) was thus conceived and applied in patients with septic shock, showing an improvements in hemodynamics with decreased vasopressor requirements and improved survival in patients admitted after a cardiac arrest.

The main benefit described with high volume hemofiltration is a hemodynamic improvement (e.g reduction in catecholamines' requirement). This improvement seems to be due to the removal of a badly defined network of middle molecular weight peptides. To remove efficiently these middle molecular peptides, a high filtration rate is needed. However, with high filtration rates, there is also a high clearance for smaller molecules, including antibiotics, electrolytes, vitamins, trace elements and amino acids.

The cascade hemofiltration system has been designed for a more efficient removal of middle molecular weight peptides with a limited solute consumption.

The goal of this study is the evaluation of the hemodynamic improvement using cascade hemofiltration in patients treated for septic shock.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patient with a septic shock diagnosed by the medical staff team.

• Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (= 1.0 mg/h of norepinephrine or epinephrine) for = 120 minutes and < 24h.

Exclusion Criteria:

• Age (years) < 18 or > 85.

• Weight >120 kg

• Thrombocytopenia 50< G/l or Neutrophils <0.5 Giga/l

• Contra indication to heparin anticoagulation.

• Patient requiring catecholamines (epinephrine = 1 mg/h or norepinephrine = 1 mg/h) for >24h.

• Patient admitted to the ICU = 7 days before the inclusion criteria.

• Comorbid conditions with an expected survival < 6 months

• Inclusion (<28 days) in another study interfering with the goals of the current investigation.

• Pregnancy

• Immune compromised patients (e.g. being treated for cancer, treated by immunosuppressors or steroids, AIDS).

Related Conditions & MeSH terms

• Sepsis
• Shock, Septic

Intervention

Device:
• Cascade
Cascade treatment over 48h

Other:
• Standard treatment
Standard therapy

Locations

Country	Name	City	State
France	CHU hospital	Clermont-Ferrand
France	Hopital Le Bocage	Dijon
France	Centre Hospitalier Marc JACQUET	Melun
France	Hopital Tenon	Paris
France	Hopital Delafontaine	Saint Denis

Sponsors (2)

Lead Sponsor	Collaborator
Baxter Healthcare Corporation	Gambro Lundia AB

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the primary outcome will be the number of days without catecholamines at the 28th day of randomization		28th day
Secondary	rate of decrease of catecholamines during the first 72h, days without mechanical ventilation at D90, days without RRT for acute renal failure at D90, days without ICU requirement at D90, status at D90.		72h, D90